Susceptibility of bacterial endophthalmitis isolates to vancomycin, ceftazidime, and amikacin

Abstract Bacterial endophthalmitis is a rare intraocular infection, and prompt administration of intravitreal antibiotics is crucial for preventing severe vision loss. The retrospective study is to investigate the in vitro susceptibility to the antibiotics vancomycin, amikacin, and ceftazidime of ba...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kuan-Jen Chen, Ming-Hui Sun, Chiun-Ho Hou, Hung-Chi Chen, Yen-Po Chen, Nan-Kai Wang, Laura Liu, Wei-Chi Wu, Hung-Da Chou, Eugene Yu-Chuan Kang, Chi-Chun Lai
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a1c39e9c570e476f9b53726a026c917a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a1c39e9c570e476f9b53726a026c917a
record_format	dspace
spelling	oai:doaj.org-article:a1c39e9c570e476f9b53726a026c917a2021-12-02T17:06:31ZSusceptibility of bacterial endophthalmitis isolates to vancomycin, ceftazidime, and amikacin10.1038/s41598-021-95458-w2045-2322https://doaj.org/article/a1c39e9c570e476f9b53726a026c917a2021-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-95458-whttps://doaj.org/toc/2045-2322Abstract Bacterial endophthalmitis is a rare intraocular infection, and prompt administration of intravitreal antibiotics is crucial for preventing severe vision loss. The retrospective study is to investigate the in vitro susceptibility to the antibiotics vancomycin, amikacin, and ceftazidime of bacterial endophthalmitis isolates in specimens at a tertiary referral center from January 1996 to April 2019 in Taiwan. Overall, 450 (49.9%) isolates were Gram positive, 447 (49.6%) were Gram negative, and 4 (0.4%) were Gram variable. In Gram-positive isolates, coagulase-negative staphylococci were the most commonly cultured bacteria (158, 35.1%), followed by Streptococci (100, 22.2%), Enterococci (75, 16.7%), and Staphylococcus aureus (70, 15.6%). In Gram-negative isolates, they were Klebsiella pneumoniae (166, 37.1%) and Pseudomonas aeruginosa (131, 29.3%). All Gram-positive organisms were susceptible to vancomycin, with the exception of one Enterococcus faecium isolate (1/450, 0.2%). Of the Gram-negative isolates, 96.9% and 93.7% were susceptible to ceftazidime and amikacin, respectively. Nine isolates (9/447, 2.0%) were multidrug-resistant Gram-negative bacteria, comprising K. pneumoniae (4/164, 2.4%), Acinetobacter baumannii (2/3, 67%), and Stenotrophomonas maltophilia (3/18, 17%). In conclusion, in vitro susceptibility testing revealed that vancomycin remains the suitable antibiotic treatment for Gram-positive endophthalmitis. Ceftazidime and amikacin provide approximately the same degree of Gram-negative coverage. Multidrug-resistant bacterial endophthalmitis was uncommon.Kuan-Jen ChenMing-Hui SunChiun-Ho HouHung-Chi ChenYen-Po ChenNan-Kai WangLaura LiuWei-Chi WuHung-Da ChouEugene Yu-Chuan KangChi-Chun LaiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Kuan-Jen Chen Ming-Hui Sun Chiun-Ho Hou Hung-Chi Chen Yen-Po Chen Nan-Kai Wang Laura Liu Wei-Chi Wu Hung-Da Chou Eugene Yu-Chuan Kang Chi-Chun Lai Susceptibility of bacterial endophthalmitis isolates to vancomycin, ceftazidime, and amikacin
description	Abstract Bacterial endophthalmitis is a rare intraocular infection, and prompt administration of intravitreal antibiotics is crucial for preventing severe vision loss. The retrospective study is to investigate the in vitro susceptibility to the antibiotics vancomycin, amikacin, and ceftazidime of bacterial endophthalmitis isolates in specimens at a tertiary referral center from January 1996 to April 2019 in Taiwan. Overall, 450 (49.9%) isolates were Gram positive, 447 (49.6%) were Gram negative, and 4 (0.4%) were Gram variable. In Gram-positive isolates, coagulase-negative staphylococci were the most commonly cultured bacteria (158, 35.1%), followed by Streptococci (100, 22.2%), Enterococci (75, 16.7%), and Staphylococcus aureus (70, 15.6%). In Gram-negative isolates, they were Klebsiella pneumoniae (166, 37.1%) and Pseudomonas aeruginosa (131, 29.3%). All Gram-positive organisms were susceptible to vancomycin, with the exception of one Enterococcus faecium isolate (1/450, 0.2%). Of the Gram-negative isolates, 96.9% and 93.7% were susceptible to ceftazidime and amikacin, respectively. Nine isolates (9/447, 2.0%) were multidrug-resistant Gram-negative bacteria, comprising K. pneumoniae (4/164, 2.4%), Acinetobacter baumannii (2/3, 67%), and Stenotrophomonas maltophilia (3/18, 17%). In conclusion, in vitro susceptibility testing revealed that vancomycin remains the suitable antibiotic treatment for Gram-positive endophthalmitis. Ceftazidime and amikacin provide approximately the same degree of Gram-negative coverage. Multidrug-resistant bacterial endophthalmitis was uncommon.
format	article
author	Kuan-Jen Chen Ming-Hui Sun Chiun-Ho Hou Hung-Chi Chen Yen-Po Chen Nan-Kai Wang Laura Liu Wei-Chi Wu Hung-Da Chou Eugene Yu-Chuan Kang Chi-Chun Lai
author_facet	Kuan-Jen Chen Ming-Hui Sun Chiun-Ho Hou Hung-Chi Chen Yen-Po Chen Nan-Kai Wang Laura Liu Wei-Chi Wu Hung-Da Chou Eugene Yu-Chuan Kang Chi-Chun Lai
author_sort	Kuan-Jen Chen
title	Susceptibility of bacterial endophthalmitis isolates to vancomycin, ceftazidime, and amikacin
title_short	Susceptibility of bacterial endophthalmitis isolates to vancomycin, ceftazidime, and amikacin
title_full	Susceptibility of bacterial endophthalmitis isolates to vancomycin, ceftazidime, and amikacin
title_fullStr	Susceptibility of bacterial endophthalmitis isolates to vancomycin, ceftazidime, and amikacin
title_full_unstemmed	Susceptibility of bacterial endophthalmitis isolates to vancomycin, ceftazidime, and amikacin
title_sort	susceptibility of bacterial endophthalmitis isolates to vancomycin, ceftazidime, and amikacin
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/a1c39e9c570e476f9b53726a026c917a
work_keys_str_mv	AT kuanjenchen susceptibilityofbacterialendophthalmitisisolatestovancomycinceftazidimeandamikacin AT minghuisun susceptibilityofbacterialendophthalmitisisolatestovancomycinceftazidimeandamikacin AT chiunhohou susceptibilityofbacterialendophthalmitisisolatestovancomycinceftazidimeandamikacin AT hungchichen susceptibilityofbacterialendophthalmitisisolatestovancomycinceftazidimeandamikacin AT yenpochen susceptibilityofbacterialendophthalmitisisolatestovancomycinceftazidimeandamikacin AT nankaiwang susceptibilityofbacterialendophthalmitisisolatestovancomycinceftazidimeandamikacin AT lauraliu susceptibilityofbacterialendophthalmitisisolatestovancomycinceftazidimeandamikacin AT weichiwu susceptibilityofbacterialendophthalmitisisolatestovancomycinceftazidimeandamikacin AT hungdachou susceptibilityofbacterialendophthalmitisisolatestovancomycinceftazidimeandamikacin AT eugeneyuchuankang susceptibilityofbacterialendophthalmitisisolatestovancomycinceftazidimeandamikacin AT chichunlai susceptibilityofbacterialendophthalmitisisolatestovancomycinceftazidimeandamikacin
_version_	1718381571843555328

Susceptibility of bacterial endophthalmitis isolates to vancomycin, ceftazidime, and amikacin

Ejemplares similares